市场调查报告书
商品编码
1470838
疫苗市场:按类型、技术类型、适应症、给药途径、年龄组划分 - 2024-2030 年全球预测Vaccines Market by Type (Monovalent Vaccine, Multivalent Vaccine), Technology Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines), Indication, Route of administration, Age Group - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年疫苗市场规模为556.6亿美元,预计2024年将达到599.4亿美元,2030年将达到941.4亿美元,复合年增长率为7.79%。
疫苗是生物製药,使人体免疫系统能有效对抗致病微生物。它的作用是刺激免疫反应并建立针对有害病原体的特异性防御机制(主要以抗体的形式)。全球感染疾病率上升和全球免疫计划的增加是这一增长的主要原因。此外,政府在疫苗研发方面的积极努力和政策也是市场开拓的动力。高昂的开发成本、漫长的测试和核准流程、产品召回问题以及部分地区的供应困难等给疫苗市场的成长带来了挑战。佐剂在疫苗中的整合、治疗性疫苗的开发以及疫苗契约製造的成长预计将为市场提供重大的成长机会。
主要市场统计 | |
---|---|
基准年[2023] | 556.6亿美元 |
预测年份 [2024] | 599.4亿美元 |
预测年份 [2030] | 941.4亿美元 |
复合年增长率(%) | 7.79% |
类型:更偏好旨在预防特定疾病的单价疫苗
单价疫苗针对一种抗原或微生物,产生强烈、集中的免疫反应。例如,麻疹疫苗通常以 MMR II 的形式施用,这是一种在世界各地广泛普及的单价疫苗。当单一疾病占主导地位并且需要特异性的免疫反应时,此类疫苗是理想的选择。多效价疫苗可刺激针对多种病原体或相同病原体菌株的免疫力。一种广泛普及的多效价疫苗是 DTP 疫苗,可预防白喉、破伤风和百日咳。多效价疫苗非常适合多种疾病同时发生的环境。单价疫苗可以更好地对抗特定疾病,多效价疫苗可以提供广泛的保护,但这两种类型对于满足世界疾病预防需求都至关重要。製造多效价疫苗需要更复杂的过程,以确保对多种病原体的功效。然而,从公共卫生的角度来看,其广泛的适用性可能物有所值。
技术类型:结合疫苗的开发正在进行中。
灭活疫苗通常是给免疫力缺乏的人开的,是透过中和病原体来生产的。由减毒活病毒开发的减毒活疫苗描述了适合强大免疫系统的长期免疫力。传讯RNA(mRNA) 疫苗是一种新型疫苗,它使用病毒 RNA 的某些副本来触发免疫反应。次单元、重组体、多醣体和结合物是由病原体的部分成分製成的,可供对某些疫苗成分过敏的人使用。类毒素疫苗旨在预防细菌产生的毒素,并提供给易受此类感染疾病的人。病毒载体疫苗的病毒表面含有编码蛋白质的 DNA,可刺激免疫反应。这些疫苗中的每一种都在预防感染疾病方面发挥着重要作用。选择主要根据患者的年龄、免疫状态和过敏倾向。新的开发、合作和发布正在丰富这一领域,并提供更好的患者照护选择。
适应症:针对严重呼吸道疾病的百白破疫苗需求不断增加
DPT 疫苗用于预防白喉、百日咳和破伤风。通常,2个月、4个月、6个月、15至18个月和4至6岁的婴幼儿会接种五剂系列疫苗以进行免疫。肝炎疫苗(包括甲型肝炎和B型肝炎)用于预防这些病毒的感染,这些病毒主要影响肝臟。两种疫苗通常分两剂接种,第二剂疫苗在第一剂接种后 6 个月接种。人类乳突病毒 (HPV) 疫苗用于预防已知会导致某些癌症(例如子宫颈癌和喉癌)的病毒感染。通常为 9 至 14 岁的青春期前儿童分两次接种,间隔 6 个月。流感疫苗通常称为“流感疫苗”,每年註射一次以预防季节性流感病毒。建议 6 个月及以上的所有人,尤其是那些有严重流感併发症风险的人,例如老年人和患有慢性疾病的人。麻疹疫苗通常作为麻疹-腮腺炎-德国麻疹(MMR) 疫苗的一部分接种,为 12 至 15 个月和 4 至 6 岁的儿童接种,以预防这些高度传染性的病毒性疾病。脑膜炎双球菌疫苗用于预防可能导致脑膜炎和血液感染等严重症状的细菌感染。脑膜炎双球菌疫苗用于预防可能导致脑膜炎和血液感染等严重症状的细菌感染。流行性腮腺炎和德国德国麻疹疫苗通常是作为 MMR 疫苗和麻疹疫苗的一部分接种。儿童注射两剂以确保免疫力。然而,即使是没有免疫力或没有疫苗接种史的成年人也可能需要接种疫苗。肺炎链球菌疫苗可预防引起肺炎、脑膜炎和血液感染等肺炎球菌疾病的细菌,适用于所有 2 岁以下儿童、65 岁以上成人以及患有某些健康状况的人。脊髓灰质炎疫苗用于预防脊髓灰质炎,这是一种导致瘫痪的高度传染性疾病。儿童通常分四剂接种:2 个月、4 个月、6 至 18 个月和 4 至 6 岁。轮状病毒疫苗可预防导致婴幼儿严重腹泻的病毒感染疾病。该疫苗通常在出生后的前 6 个月内口服 2 至 3 剂。接种水痘疫苗是为了预防传染性很强的水痘。疫苗通常分两剂接种,第一剂在 12 至 15 个月大时接种,第二剂在 4 至 6 岁时接种。
给药途径:越来越多地采用口服给药来延长免疫反应,以获得更持久的疫苗
最常见的疫苗接种方法是肌肉注射和皮下注射。这种给药途径使疫苗保持在肌肉内或皮下注射,促进有效的免疫反应。当不希望透过针头给药或不切实际时,通常使用口服给药。轮状病毒、脊髓灰质炎(OPV) 和霍乱的口服治疗已被证明是有效且易于管理的。两种给药途径均具有独特的优势,包括肌肉或皮下给药的快速免疫和口服给药的无针便利性。然而,每种疫苗都有缺点,例如肌肉注射和皮下注射会带来疼痛和针刺伤,以及口服疫苗会因胃肠道状况而受到限制。疫苗的选择取决于个人疫苗、接种者和医疗保健环境。对非侵入性疫苗接种方法的探索预计将促进产业研究和伙伴关係。
年龄层: 人类乳突病毒(HPV)疫苗效用的增加增加了儿童用疫苗作为预防措施的采用
18岁及以上的成年人口占据了疫苗市场的大部分。该群体主要需要疫苗来增强免疫力、预防疾病、满足旅游免疫需求。疫苗市场的儿童部分主要针对 18 岁以下的儿童。必要的免疫接种、疾病预防和遵守最高医疗建议是这一类别的主要动力。成人疫苗市场非常注重预防和维护,而儿童市场则主要注重预防。
区域洞察
在亚太地区,中国、印度和日本等强劲经济体的疫苗市场呈现显着成长,人口密度高、感染疾病爆发率高,需要全面免疫。由于人口结构和广泛的公共卫生基础设施,包括美国和加拿大在内的美洲对疫苗的需求很高。对疫苗研发(R&D)的大量投资、最近的专利和倡议进一步支持了成长。欧洲、中东和非洲的经济格局不同,消费者行为也各不相同。欧盟(EU)拥有强大的医疗保健系统,需要大规模的疫苗接种计画。中东和非洲市场成长潜力大。印度血清研究所和非洲疫苗采购信託基金之间的 2022 年 COVID-19 供应合作等措施是塑造这一格局的关键变化。
FPNV定位矩阵
FPNV定位矩阵对于评估疫苗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对疫苗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析也为此细分市场的竞争特征提供了宝贵的见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:包括新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:包括对未来技术、研发活动以及突破性产品开发的智力见解。
1.疫苗市场的市场规模和预测是多少?
2.疫苗市场预测期内我们应该考虑投资哪些产品与应用?
3. 疫苗市场的技术趋势和法规结构是什么?
4.疫苗市场主要厂商的市场占有率是多少?
5. 进入疫苗市场的适当形式和策略手段是什么?
[194 Pages Report] The Vaccines Market size was estimated at USD 55.66 billion in 2023 and expected to reach USD 59.94 billion in 2024, at a CAGR 7.79% to reach USD 94.14 billion by 2030.
Vaccines are biological preparations that equip the body's immune system with the capability to combat disease-causing microbes effectively. They work by stimulating the immune response to generate a specific defense mechanism, predominantly in the form of antibodies, against harmful pathogens. The rising incidence of infectious diseases globally and the rise in immunization programs worldwide significantly influence this growth. Moreover, favorable government initiatives and policies for vaccine development are also driving market growth. High development costs, lengthy testing and approval process issues over product recalls, and inaccessibility in a few regions pose challenges to the growth of the vaccine market. Integration of adjuvants in vaccines, development of therapeutic vaccines, and growth in the contract manufacturing of the vaccines are expected to create significant growth opportunities in the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 55.66 billion |
Estimated Year [2024] | USD 59.94 billion |
Forecast Year [2030] | USD 94.14 billion |
CAGR (%) | 7.79% |
Type: Significant preference for monovalent vaccines for specific disease prevention
Monovalent vaccines target one antigen or microorganism, producing a potent, focused immune response. For instance, the measles vaccine, commonly delivered in the M-M-R II format, is a globally prevalent monovalent vaccine. Such vaccines are ideal when single diseases dominate, requiring a specific immune response. Multivalent vaccines stimulate immunity against multiple pathogens or strains of the same pathogen. A widespread multivalent vaccine is the DTP vaccine, which safeguards against Diphtheria, Tetanus, and Pertussis. Multivalent vaccines are best suited for environments with multiple concurrent diseases. Even though monovalent vaccines excel in combating specific illnesses and multivalent vaccines offer broad-scope protection, both types are indispensable for addressing global disease prevention needs. Crafting multivalent vaccines requires a more intricate process to ensure efficacy against various pathogens. Nevertheless, their vast coverage could present superior, cost-effective advantages from a public health standpoint.
Technology Type: Rising development in the conjugate vaccines as an viable alternative
Inactivated vaccines, typically prescribed for the immune-compromised, are produced by neutralizing a pathogen. Live-attenuated vaccines, developed from a live yet weakened virus, provide prolonged immunity suitable for robust immune systems. Messenger RNA (mRNA) vaccines, a new breed of vaccines, use a copy of a part of the virus's RNA to provoke an immune response. Subunit, recombinant, polysaccharide, and conjugate vaccines are made from a piece of the pathogen that can be utilized by those allergic to certain vaccine components. Toxoid vaccines are designed to protect against bacteria-produced toxins, and are provided to individuals prone to such infections. Viral vector vaccines function by carrying a piece of DNA that codes for a protein found on the virus surface to stimulate an immune response. Each of these types of vaccines plays a crucial role in preventing infectious diseases. The selection depends mainly on the patient's age, immune status, or predisposed allergies. New developments, collaborations, and launches have further enriched this field, providing better patient care options.
Indication: Growing need for DPT vaccine for protection against serious respiratory ailments
The DPT vaccine is administered to protect against diphtheria, pertussis (whooping cough), and tetanus. It's typically given in a series of five shots to infants and toddlers at two months, four months, six months, 15-18 months, and 4-6 years of age to develop immunity. Hepatitis vaccines, including Hepatitis A and B, are administered to prevent these viral infections that primarily affect the liver. Both vaccines are usually given as two shots, with the second dose delivered six months after the first. The Human Papillomavirus (HPV) vaccine is given to protect against the viral infection known to cause certain types of cancers, such as cervical and throat cancer. It is usually given to preadolescents aged 9-14 over two doses six months apart. The influenza vaccine, typically known as the 'flu shot,' is given annually to protect against seasonal flu viruses. It's recommended for everyone over the age of 6 months, particularly those at risk of severe flu complications, such as the elderly and people with chronic health conditions/ The Measles vaccine is commonly given as part of the measles, mumps, and rubella (MMR) vaccine, and administered in a series of two doses at 12-15 months and 4-6 years of age to protect against these highly contagious viral diseases. The Meningococcal vaccine is given to protect against bacterial infections that can lead to severe conditions such as meningitis and bloodstream infections. It's usually administered to preteens and teenagers and includes a booster shot in the late teens. Mumps and Rubella vaccines are typically given as part of the MMR vaccine and measles. Two doses are given in childhood to ensure immunity. However, adults without immunity or vaccination records may also require vaccination. The Pneumococcal vaccine protects against types of bacteria that cause pneumococcal disease, including pneumonia, meningitis, and bloodstream infections, for all children under the age of 2, adults 65 years and above, and individuals with specific health conditions. The Polio vaccine is given to prevent poliomyelitis, a highly infectious disease that leads to paralysis. Children typically receive four doses at two months, four months, 6-18 months, and 4-6 years. The Rotavirus vaccine protects against a viral infection provoking severe diarrhea in infants and young children. It's typically given orally in two or three doses during the first six months of life. The Varicella vaccine is administered to protect against chickenpox, a highly contagious disease. It's typically given in two doses, with the first dose at 12-15 months and the second at 4-6 years of age.
Route of administration: Increasing adoption of oral vaccines for longer-lasting immune responses
Intramuscular and Subcutaneous administrations are the most common methods for vaccine delivery. This route allows the vaccine to be retained in the muscle or beneath the skin, promoting an efficient immune response. The oral route of vaccine administration is a popular alternative often used when needle-based administration is not preferred or practical. Oral vaccines, such as those for rotavirus, polio (OPV), and cholera, have proven effective and easy to administer. Both administration routes have unique advantages, such as swift immunity in intramuscular and subcutaneous administration and needle-free convenience with oral vaccines. However, they each have drawbacks, such as pain and needle-stick injuries from intramuscular and subcutaneous injections or restrictions due to gastrointestinal conditions for oral vaccines. Vaccine selection depends upon the individual vaccine, recipient, and healthcare environment. Advancements in non-intrusive vaccination methods are anticipated to drive industry research and partnerships.
Age Group: wider adoption of pediatric vaccine as a preventive measure owing to rising HPV vaccine usability
The adult population, considered those over the age of 18, comprises the more significant portion of the vaccine market. This group primarily requires vaccines to boost their immunity, prevent diseases, and meet the needs of travel vaccinations. The pediatric segment of the vaccine market focuses on children under the age of 18. Necessary immunizations, disease prevention, and peak medical advisory compliance primarily drive this category. While the adult vaccine market excels in prevention and maintenance, the pediatric section is fundamentally preventive.
Regional Insights
In Asia-Pacific, robust economies such as China, India, and Japan have exhibited significant growth in vaccine markets due to large population densities and high prevalence of infectious diseases, necessitating comprehensive immunization drives. There's a high need for vaccines in the Americas, comprising countries such as the United States and Canada, owing to the demographic makeup and an expansive public health infrastructure. Significant investments in research and development (R&D) of vaccines, recent patents, and initiatives further fuel the growth. The EMEA region, with diverse economic landscapes, displays varying consumer behavior. The European Union, with well-funded health systems, necessitates extensive immunization programs. The Middle East and Africa possess a significant potential for market growth. Initiatives such as the collaboration between the Serum Institute of India and the Africa Vaccine Acquisition Trust in 2022 to supply COVID-19 vaccines are pivotal changes reshaping this landscape.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, Chongqing Zhifei Biological Products Co.,Ltd., CSL Limited, CureVac SE, Daiichi Sankyo Co., Ltd., Emergent BioSolutions Inc., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mitsubishi Chemical Group Corporation, Moderna Inc., Novavax, Inc., Pfizer Inc., Sanofi Group, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Zydus Lifesciences Limited.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Vaccines Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccines Market?
3. What are the technology trends and regulatory frameworks in the Vaccines Market?
4. What is the market share of the leading vendors in the Vaccines Market?
5. Which modes and strategic moves are suitable for entering the Vaccines Market?